Date | Time | Source | Headline | Symbol | Company |
05/02/2024 | 2:07PM | iHub Newswire | FeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | | |
02/22/2010 | 4:00PM | PR Newswire (US) | Dendreon Reports Fourth Quarter and 2009 Year End Financial Results | NASDAQ:DNDN | N^CURN |
02/11/2010 | 5:00PM | PR Newswire (US) | Dendreon to Host Conference Call on February 22 to Announce Fourth Quarter and Full Year 2009 Results | NASDAQ:DNDN | |
02/03/2010 | 7:30AM | PR Newswire (US) | Dendreon Announces Webcast Presentation at 12th Annual BIO CEO and Investor Conference | NASDAQ:DNDN | |
01/05/2010 | 7:30AM | PR Newswire (US) | Dendreon Announces Webcast Presentation at 28th Annual J.P. Morgan Healthcare Conference | NASDAQ:DNDN | |
12/11/2009 | 6:13PM | PR Newswire (US) | Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering | NASDAQ:DNDN | |
12/10/2009 | 7:48PM | PR Newswire (US) | Dendreon Announces Pricing of Common Stock Offering | NASDAQ:DNDN | |
12/10/2009 | 6:30AM | PR Newswire (US) | Dendreon Appoints Hans Bishop as Chief Operating Officer | NASDAQ:DNDN | |
12/08/2009 | 5:09PM | PR Newswire (US) | Dendreon Announces Proposed Public Offering of Common Stock | NASDAQ:DNDN | |
11/25/2009 | 7:30AM | PR Newswire (US) | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences | NASDAQ:DNDN | |
11/20/2009 | 8:30AM | PR Newswire (US) | Dendreon Receives FDA Acknowledgement of Complete Response | NASDAQ:DNDN | |
11/11/2009 | 4:00PM | PR Newswire (US) | Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization | NASDAQ:DNDN | |
11/02/2009 | 8:30AM | PR Newswire (US) | Dendreon Completes Submission of Biologics License Application for PROVENGE | NASDAQ:DNDN | |
10/30/2009 | 7:30AM | PR Newswire (US) | Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET | NASDAQ:DNDN | |
10/29/2009 | 7:30AM | PR Newswire (US) | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences | NASDAQ:DNDN | |
10/12/2009 | 12:59PM | PR Newswire (US) | Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors | NASDAQ:DNDN | |
09/24/2009 | 12:51PM | Dow Jones News | 2nd UPDATE: Dendreon Says Provenge Launch, Filing On Track | NASDAQ:DNDN | Dendreon Corp. |
09/24/2009 | 11:30AM | Dow Jones News | UPDATE:Dendreon Sees Up To $2.5 Billion In Provenge Revenue If OK'd | NASDAQ:DNDN | Dendreon Corp. |
09/24/2009 | 9:54AM | Dow Jones News | Dendreon Expects To File For Provenge Marketing Approval In Mid-Nov | NASDAQ:DNDN | Dendreon Corp. |
09/04/2009 | 5:43PM | PR Newswire (US) | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences | NASDAQ:DNDN | |
08/27/2009 | 7:30AM | PR Newswire (US) | Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009 | NASDAQ:DNDN | |
08/11/2009 | 7:00AM | PR Newswire (US) | Dendreon Reports Second Quarter 2009 Financial Results | NASDAQ:DNDN | |
07/30/2009 | 7:30AM | PR Newswire (US) | Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET | NASDAQ:DNDN | |
06/05/2009 | 7:30AM | PR Newswire (US) | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences | NASDAQ:DNDN | |
05/14/2009 | 7:30AM | PR Newswire (US) | Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacif | NASDAQ:DNDN | |
05/13/2009 | 11:08AM | PR Newswire (US) | Dendreon Announces Closing of Common Stock Offering | NASDAQ:DNDN | |
05/08/2009 | 6:30AM | PR Newswire (US) | Dendreon Announces Common Stock Offering | NASDAQ:DNDN | |
05/07/2009 | 7:30AM | PR Newswire (US) | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences | NASDAQ:DNDN | |
05/06/2009 | 7:30AM | PR Newswire (US) | Dendreon Reports First Quarter 2009 Financial Results | NASDAQ:DNDN | |
04/30/2009 | 10:37AM | PR Newswire (US) | TryPennyStocks.com Issues Hot Stocks On The Move Today: WFC, BRCD, DNDN, GS, FITB, MS, ETFC | NASDAQ:DNDN | |